Nanoparticulate and molecular adjuvants have shown great efficacy in enhancing immune responses, and the immunogenic vaccines of the future will most likely contain both. To investigate the immunostimulatory effects of molecular adjuvants on nanoparticle vaccines, we have designed ovalbumin (OVA) protein nanoparticles coated with two different adjuvants-flagellin (FliC) and immunoglobulin M (IgM). These proteins, derived from Salmonella and mice, respectively, are representatives of pathogen-and host-derived molecules that can enhance immune responses. FliC-coated OVA nanoparticles, soluble FliC (sFliC) admixed with OVA nanoparticles, IgM-coated nanoparticles, and OVAcoated nanoparticles were assessed for immunogenicity in an in vivo mouse immunization study.
| I N T R O D U C T I O N
Nanoparticle vaccine delivery systems have emerged as an attractive means of enhancing subunit vaccine adjuvancy. Particulate vaccine carriers can control release of soluble antigens to the immune system and protect them from degradation.
1 However, nanoparticles have been found to be more than just passive antigen depots, and certain types of particles exhibit their own immunostimulatory effects on antigen presenting cells. The exact nature of this nanoparticulate-mediated adjuvancy is unknown, and many fundamental studies have examined the immunological effects of nanoparticle properties such as size, 2 surface charge, 3 shape, 4 and material. 5 Generalized vaccine particle design principles are difficult to elucidate from these studies, however, due to our incomplete understanding of immunology of vaccination, and specifically the type of immune response needed to successfully vaccinate against a particular pathogen. 6 The molecular adjuvants are a more predictable class of immunostimulants. Pathogen-associated molecular patterns (PAMPs) are macromolecules that interact with specific pattern recognition receptors (PRRs) on or inside antigen presenting cells. 1, 7 Receptors that bind bacterially-derived or virally-derived macromolecules are hypothesized to initiate adaptive immune responses geared toward those particular classes of pathogens. 7, 8 Toll-like receptors (TLRs) are a class of membrane-bound PRRs that have been extensively studied for vaccine adjuvant use. [9] [10] [11] However, safety concerns over administration of pathogen-derived compounds require thorough investigation. 12 Currently, several pathogen-derived vaccine adjuvants are undergoing clinical trials, but only two have been approved for use in humans. Flagellin (FliC) is a TLR-5 ligand shown to greatly enhance responses to influenza vaccination. 14, 15 Given the strength of FliC as an adjuvant, vaccines have been proposed with genetic fusion of antigenic peptides with the FliC protein, 11, 16 as well as nanoparticles decorated with FliC. 17, 18 As of this writing, at least six clinical trials have been completed with FliC-fusion proteins. 19 The propensity of certain FliC-fusion proteins to aggregate, even at 48C, may decrease their efficacy, 11 and the sequence-dependent nature of FliC-fusion protein stability reduces its attractiveness as a platform technology. Nanoparticles with a stable, native FliC coat, or with native FliC admixed can combine the immunostimulatory properties of FliC with those of antigencontaining nanoparticles. The optimal location of antigen and adjuvant in nanoparticle vaccine formulations is still under active research, 9, 20 and recent findings suggest that flagellated bacteria in the gut assist in TLR-5-mediated adjuvancy to subcutaneously administered influenza vaccines. 14 Using TLR ligands as adjuvants, however, poses the risk of safety issues 11 and immune responses against the adjuvant itself. 21 The use of host-derived proteins as vaccine adjuvants may be able to address some of the issues associated with pathogen-derived adjuvants. Antibodies, or immunoglobulins (Ig), coat pathogens during the immune response to an infection, and these proteins may be able to act as in situ adjuvants rendering nanoparticles more immunogenic in vivo.
While antibodies immobilized by affinity interactions on the nanoparticles' surface should remain bound, any soluble Ig in the formulation should be recognized as host protein and consequently nonimmunogenic, and would simply enter the host's circulating repertoire of antibodies. Additionally, the current, widespread good manufacturing practice production of humanized antibodies offers a pathway for largescale production of immunoglobulin-based adjuvants.
The idea of immunoglobulin-mediated adjuvancy has been explored through the use of antibody-bound antigen, or immune complexes, as vaccines. [22] [23] [24] [25] 
| FliC expression and purification
The plasmid pET22b-flic was used to express recombinant FliC from Salmonella typhimurium. 35 The plasmid was transformed into E. coli BL21 for expression. Transformed E. coli were grown in 1-L Luria Bertani broth with 100 lg/ml ampicillin from 10 ml overnight cultures.
Expression was induced after approximately 2 hr (OD 600 0.6) with 0.25 mM isopropyl b-D21-thiogalactopyranoside (IPTG). Recombinant
FliC was expressed over 24 hr and purified using native Ni-affinity purification according to the manufacturer's instructions (Ni-NTA agarose, Qiagen, Valencia, CA). Protein concentration was assessed with a bicinchoninic acid (BCA) assay according to the manufacturer's instructions (Thermo Fisher Scientific), and purity was assessed by SDS-PAGE and Western Blot (Supporting Information Figure S1 ).
| Nanoparticle synthesis and characterization
The 270-nm OVA PNP cores were made as previously described. 34 Briefly, 0.4 ml pure ethanol was added at a constant rate to 0.1 ml of 6.2 mg/ml OVA in PBS under constant stirring at 600 rpm. The amine-
(ThermoFisher Scientific) was used to stabilize the resulting nanoparticles. The nanoparticles were cross-linked in 0.82 mM DTSSP while stirring at room temperature for 1 hr, followed by centrifugation to collect the particles and resuspension in PBS by sonication.
OVA PNP cores were coated with FliC by resuspension in 0.9 mg/ ml FliC in PBS, and stirred at 600 rpm overnight at 48C. Coated particles were collected by centrifugation, and resuspended in 5.26 lM DTSSP to stabilize the adsorbed coat. After stirring at 600 rpm for 1 hr at 48C, the cross-linking reaction was quenched with 50 mM Tris base, and the particles were resuspended by sonication in PBS.
OVA PNP cores were coated with IgM by affinity immobilization. Nanoparticle size distribution and zeta potential were assessed by dynamic light scattering and electrophoretic light scattering, respectively, with a Malvern Zetasizer Nano ZS (Malvern Instruments, Westborough, MA). Nanoparticle concentration was assessed with a BCA assay according to the manufacturer's instructions (Thermo Scientific).
Nanoparticles were resuspended in water, air-dried, and sputter-coated with palladium prior to visualization with a Zeiss Ultra60 FE (Carl Zeiss Microscopy, Cambridge, UK) scanning electron microscope at 5.0 kV. fetal bovine serum (FBS), and cultured in humidified 5% CO 2 at 378C.
| IgM coating characterization

| FliC coating characterization
Cells were incubated overnight at a density of 2 3 10 6 cells/well in a 6-well plate, and transfected the following day with 10 lg pUNO1- Nanoparticles were suspended in fresh DMEM 1 1% FBS at a concentration of 1 lg/mL and used to stimulate transfected cells for 8 hr.
Bright-Glo Luciferase Assay reagent (Promega, Madison, WI) was diluted 1:1 with serum-free DMEM and used to assess luciferase activity according to the manufacturer's instructions.
| Immunization
All animal work was compliant with the NIH Guide for the Care and
Use of Laboratory Animals and all protocols and procedures employed were reviewed and approved by the Emory University Institutional Animal Care and Use Committee. Seven-week old female Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were given 50 ll intramuscular (i.
m.) injections into the right hind-leg of 0.2 mg/ml nanoparticle formulations as described in Table 1 . Injections were repeated 21 days after priming for a boost administration.
| Sample collection
Blood was collected from immunized mice by submandibular venipuncture 2 weeks after prime and boost immunizations. Blood was allowed to clot at 48C for at least 30 min, and was centrifuged at 5,000 rpm for 5 min to collect serum. Serum samples were stored at 2208C for further analysis.
Following euthanasia on Day 39, splenocytes were prepared from mouse spleens. Briefly, spleens extracted from mice were homogenized manually with the plunger of a 1 ml syringe and cells collected by centrifugation at 3003g for 5 min. Cells collected were resuspended in red blood cell lysis buffer (150 mM NH 4 Cl, 10 mM NH 4 HCO 3 , 1 mM Na 2 EDTA, pH 7.4) for 5 min at room temperature, quenched with RPMI 1640 media (ATCC, Manassas, VA) and centrifuged for 5 min at 2,3003g. Splenocytes collected were resuspended in RPMI 1640 at 48C and counted by flow cytometry (BD Accuri c6, BD Biosciences, San Jose, CA).
| Serum antibody assessment
OVA-specific IgG antibody titers were assessed by ELISA, as previously described. 10 Briefly, serial twofold dilutions of serum were analyzed using a standard ELISA procedure, with 1 lg/ml OVA in PBS as the capture antigen, 1% BSA in PBS as the blocking solution, and 1 lg/ml HRP-anti-mouse IgG in 1% BSA solution as the detection antibody.
Chromogenic quantification was assessed by the oxidation of tetramethylbenzidine by hydrogen peroxide (R&D Systems, Minneapolis, MN)
according to the manufacturer's instructions. Two times the absorbance of naïve group's serum samples was considered the cutoff for measuring the endpoint titer.
OVA-specific IgG1 and IgG2a concentrations were also assessed by ELISA as described above, using HRP-conjugated anti-mouse IgG1
and IgG2a, and monoclonal mouse IgG1-or IgG2a-anti-OVA to create a standard curve (Chondrex, Redmond, WA).
| Cytokine ELISpot
Splenocytes were seeded at a density of 2.5 3 10 6 cells/ml on interferon g (IFN-g) and interleukin 4 (IL-4) 96-well ELISpot membranes (R&D Systems, Minneapolis, MN). Splenocytes were stimulated with or without 50 lg/ml endotoxin-free OVA, and incubated at 378C in humidified air with 5% CO 2 for 36 hr. ELISpot membranes were developed according to the manufacturer's instructions. Wells were imaged using a dissection microscope (Olympus SZX16, Olympus Corporation, Tokyo, Japan), and spots were counted using ImageQuant TL's colony counting software (GE Healthcare, Pittsburgh, PA).
| Flow cytometry
Splenocytes were seeded at a density of 2.5 3 10 6 cells/ml on 96-well plates, and stimulated with or without 50 lg/ml endotoxin-free OVA, and incubated at 378C in humidified air with 5% CO 2 for 60 hr. Cells 
| Statistical analysis
Serum antibody titers were analyzed using the Mann-Whitney U test.
Antibody concentrations and T cell counts were analyzed using oneway analysis of variance (ANOVA) followed by Sidak's multiple comparisons test. Comparisons between two groups were performed using Student's t-test. All statistical analyses were conducted using GraphPad Prism 6 (GraphPad, La Jolla, CA). The p values of p < .05 were considered statistically significant (*p < .05, **p < .01). To test our hypotheses, statistical comparisons were assessed between G1 and G3, between G2 and G4, and for T cell counts, between G6 and all other groups.
Comparisons between these groups that were significant are noted in the figures, while comparisons that were not significant are not shown.
| R E S U L T S 3.1 | Coated PNP synthesis and characterization
Monodisperse, 270 nm OVA nanoparticles were made as previously described. 34 Coating the nanoparticles did not significantly alter nanoparticle size (Figure 1a ). IgM-coating the nanoparticles without a soluble OVA quenching step resulted in large, 1,000 nm particles, suggesting 
| Coat activity
Coat activity was confirmed by testing FliC and IgM functionality. Since
FliC is a TLR-5 agonist, FliC-coated nanoparticles were used to activate a TLR-5-dependent luciferase assay. FliC-coated OVA nanoparticles activated TLR-5 signaling, and did not significantly differ in activity compared to soluble FliC admixed with OVA nanoparticles (Figure 2a ).
IgM's ability to activate complement was assessed by incubating IgMcoated nanoparticles with human serum and using ELISA to detect activated complement. 36 Uncoated OVA nanoparticles were found to activate complement, and the IgM coating on these particles did not significantly enhance complement activation (Figure 2b ).
| Antibody production
Anti-OVA serum IgG titers were assessed 2 weeks after priming and boosting (Table 1) 
| T cell cytokines
ELISpot was used to examine the ability of OVA-stimulated spleno- 
| DISCUSSION
Our previous work with OVA nanoparticles highlighted the importance of protein nanoparticle coating in altering dendritic cell inflammatory responses. 34 In addition to coating our nanoparticles with antigen, the current study explores the in vivo immune responses to pathogen-and host-derived adjuvant coatings on to nanoparticles.
| Flagellin-mediated adjuvancy
When OVA-FliC nanoparticles (G2) and OVA nanoparticles admixed with soluble flagellin (G4) were used to immunize mice, both groups developed similar levels of anti-OVA IgG titers ( Figure 3 ) and serum anti-OVA IgG1/IgG2a concentrations (Figure 4) . The production of response. 17 However, the most drastic difference between the two forms of FliC adjuvant presentation was that affinity maturation of anti-OVA serum antibodies was triggered by G2, but not by G4.
The phenomena of affinity maturation and class switching have classically been reported in the literature to occur in parallel upon immunization or infection. 7 To the best of our knowledge, only recently have the two phenomena been studied independently of one another. 38 Our observation that different modes of FliC presentation lead to differences in affinity maturation while not affecting class switching to IgG2a supports growing evidence that adjuvant presentation method can influence the resulting immune response. 
| IgM as a host-derived adjuvant
Potential safety issues have been raised for TLR ligand-based adjuvants that may dissociate or diffuse away from the antigen. 6 Unlike FliC, host-derived IgM that may dissociate from the nanoparticles is probably not going to be seen as immunogenic as soluble FliC, and thus an OVA nanoparticle 1 soluble IgM group was not included in the study design.
Antibodies have been proposed as host-derived adjuvants before. 33, 40 Most of these studies have been with soluble immune complexes consisting of soluble antigen bound to a cognate antibody. 41, 42 This strategy targets the antigen to Fc receptor-bearing antigen presenting cells, yet does not exploit a second feature of antibodymediated adjuvancy-the activation of complement.
Complement activation can be triggered by the proximity of two IgG Fc domains, or one IgM Fc domain exposed upon antigen binding. 32 Activation of complement is necessary for vaccination not only as an innate host defense mechanism, 7 but also for bridging innate and adaptive immune responses. 43 
| Summary
In this work, we tested the efficacy of a host-derived adjuvant, IgM, as well as the use of a pathogen-derived adjuvant both on nanoparticles and admixed with them. Our results are summarized in Table 2 . Our Other work has shown that delivery of two types of adjuvants in separate particles elicits greater effects compared to adjuvant co-delivery in the same particle. 9 Perhaps our most surprising finding was that antibody affinity maturation and IgG2a class switching did not correlate with one another.
While the two processes are normally associated with each other in the development of an antibody response, 7 we found that unadjuvanted OVA nanoparticles and FliC-coated OVA nanoparticles triggered affinity maturation, while IgM-and soluble FliC-adjuvanted nanoparticles did not. Our results stand in contrast to those by Corley et al., who
showed that IgM-bound soluble antigen (IgM-ICs) accelerates affinity maturation responses to T-dependent antigens. 47 Future work should examine the differences in immune responses to soluble and nanoparticulate immune complexes, and whether such a difference can be exploited to tune the affinity of the humoral immune response. Affinity maturation is necessary for generating high affinity, neutralizing antibodies, which can be protective against highly conserved pathogens. 48 For pathogens that mutate or change yearly, such as influenza, however, the generation of high-affinity neutralizing antibodies results in a loss of antibody diversity, and can contribute to the phenomenon known as original antigenic sin, in which antibodies are only made to epitopes found on the first strain of virus the immune system encountered. 7 If vaccine adjuvants can delay the affinity maturation process while promoting diversification of antibody effector functions via class switching, it is possible that the memory B cell repertoire generated from the immunization will be more effective at combatting rapidly mutating pathogens.
| C O NC LU S I O N
As vaccination moves away from the isolate-inactive-inject paradigm 49 and toward more engineered vaccine formulations for directing the immune response, the interplay between particulate and molecular adjuvants needs to be understood. We examined the role of adjuvant location on model OVA PNPs with flagellin, and found that FliC location directs the affinity maturation response. To sidestep potential issues with pathogen-derived adjuvant toxicity, we also explored using immunoglobulins as a host-derived, immunostimulatory adjuvant coating on nanoparticles. We found that although IgM coating on OVA nanoparticles does not significantly enhance complement activation in vitro, it does enhance antibody and memory T cell responses in vivo,
while not promoting affinity maturation. Further studies need to be done to investigate the effector functions of other classes of immunoglobulin adsorbed to nanoparticles, and if the delayed affinity maturation responses we see with our vaccine nanoparticles can translate to protective immune responses in in vivo challenge models of highly mutable pathogens.
